NewAmsterdam Pharma (NAMS) Enterprise Value (2021 - 2026)

NewAmsterdam Pharma has disclosed Enterprise Value across 6 years of filings, most recently posting -$458.9 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$458.9 million, up 43.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$458.9 million (up 43.23% YoY), and the FY2025 annual result was -$491.3 million, up 41.1% from the prior year.
• Enterprise Value came in at -$458.9 million for Q1 2026 at NewAmsterdam Pharma, up from -$491.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$340.4 million in Q4 2023 to a low of -$834.2 million in Q4 2024.
• The 5-year median for Enterprise Value is -$468.2 million (2023), against an average of -$531.8 million.
• Across the five-year window, Enterprise Value tumbled 636.64% in 2022 and surged 43.23% in 2026, its largest moves.
• NewAmsterdam Pharma's Enterprise Value stood at -$447.4 million in 2022, then increased by 23.9% to -$340.4 million in 2023, then sank by 145.03% to -$834.2 million in 2024, then surged by 41.1% to -$491.3 million in 2025, then rose by 6.59% to -$458.9 million in 2026.
• The last three Enterprise Value figures came in at -$458.9 million (Q1 2026), -$491.3 million (Q4 2025), and -$702.9 million (Q3 2025), per Business Quant data.